152 related articles for article (PubMed ID: 32700644)
21. Impact of CYP2C9-Interacting Drugs on Warfarin Pharmacogenomics.
Agrawal S; Heiss MS; Fenter RB; Abramova TV; Perera MA; Pacheco JA; Smith ME; Rasmussen-Torvik LJ; George AL
Clin Transl Sci; 2020 Sep; 13(5):941-949. PubMed ID: 32270628
[TBL] [Abstract][Full Text] [Related]
22. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
[TBL] [Abstract][Full Text] [Related]
23. New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model.
Rodríguez-Fernández K; Reynaldo-Fernández G; Reyes-González S; de Las Barreras C; Rodríguez-Vera L; Vlaar C; Monbaliu JM; Stelzer T; Duconge J; Mangas-Sanjuan V
Biomed Pharmacother; 2024 Jan; 170():115977. PubMed ID: 38056237
[TBL] [Abstract][Full Text] [Related]
24. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
25. The effects of
Akdeniz CS; Cevik M; Canbolat IP; Yurdakul S; Cagatay P; Ciftci C; Karaalp A; Susleyici B
Future Cardiol; 2020 Nov; 16(6):645-654. PubMed ID: 32583677
[No Abstract] [Full Text] [Related]
26. Prediction of sensitivity to warfarin based on VKORC1 and CYP2C9 polymorphisms in patients from different places in Colombia.
Cifuentes RA; Murillo-Rojas J; Avella-Vargas E
Biomedica; 2016 Mar; 36(1):91-100. PubMed ID: 27622442
[TBL] [Abstract][Full Text] [Related]
27. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
[TBL] [Abstract][Full Text] [Related]
28. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
An SH; Lee KE; Chang BC; Gwak HS
J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
[TBL] [Abstract][Full Text] [Related]
29. Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms.
Kubo K; Ohara M; Tachikawa M; Cavallari LH; Lee MTM; Wen MS; Scordo MG; Nutescu EA; Perera MA; Miyajima A; Kaneko N; Pengo V; Padrini R; Chen YT; Takahashi H
Pharmacogenomics J; 2017 Dec; 17(6):494-500. PubMed ID: 27503578
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
[TBL] [Abstract][Full Text] [Related]
31. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG
Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
[TBL] [Abstract][Full Text] [Related]
32. Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit.
Biswas M; Bendkhale SR; Deshpande SP; Thaker SJ; Kulkarni DV; Bhatia SJ; Rajadhyaksha AG; Gogtay NJ; Thatte UM
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S13-S19. PubMed ID: 30595245
[TBL] [Abstract][Full Text] [Related]
33. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
34. [Population pharmacokinetic/pharmacodynamic modeling of warfarin by nonlinear mixed effects model].
Lin RF; Lin WW; Wang CL; Huang PF; Fang SJ
Yao Xue Xue Bao; 2015 Oct; 50(10):1280-4. PubMed ID: 26837174
[TBL] [Abstract][Full Text] [Related]
35. Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses.
Ohara M; Takahashi H; Lee MT; Wen MS; Lee TH; Chuang HP; Luo CH; Arima A; Onozuka A; Nagai R; Shiomi M; Mihara K; Morita T; Chen YT
PLoS One; 2014; 9(8):e105891. PubMed ID: 25148255
[TBL] [Abstract][Full Text] [Related]
36. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
[TBL] [Abstract][Full Text] [Related]
37. Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin.
Arunkumar G; Vishnuprabu D; Nupur B; Vidyasagaran T; Murugan AK; Munirajan AK
Drug Discov Ther; 2017; 11(4):198-205. PubMed ID: 28867752
[TBL] [Abstract][Full Text] [Related]
38. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Ghozlan MF; Foad DA; Darwish YW; Saad AA
Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
[TBL] [Abstract][Full Text] [Related]
39. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.
Dilge Taşkın B; Kula S; Ergün MA; Altun D; Olguntürk R; Tunaoğlu FS; Oğuz AD; Gürsel T
Anatol J Cardiol; 2016 Oct; 16(10):791-796. PubMed ID: 27182616
[TBL] [Abstract][Full Text] [Related]
40. Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients.
Zhuang W; Wen W; Xuan B; Chen Y; Cao Y; Sun Z; Ma J
Blood Coagul Fibrinolysis; 2015 Mar; 26(2):167-74. PubMed ID: 25304014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
